Indian Dermatology Online Journal最新文献

{"title":"Changes in the Cutaneous Nerve Fiber Staining and Distribution of PGP9.5 in Clinically Uninvolved Skin in Leprosy Patients after Completion of Multidrug Therapy and Assessing PGP9.5 as a Marker of Treatment Response.","authors":"Vishal Thakur, Tarun Narang, Anuradha Bishnoi, Garima Dhawan, Ankur Sharma, Uma Nahar Saikia, T Muhammad Razmi, Sunil Dogra, Sanjeev Handa, Manish Modi","doi":"10.4103/idoj.idoj_233_23","DOIUrl":"https://doi.org/10.4103/idoj.idoj_233_23","url":null,"abstract":"<p><strong>Background: </strong>Subclinical involvement of nerves may sometimes be present much before the overt clinical manifestations become apparent. Protein gene product (PGP) 9.5, a ubiquitin-C-terminal hydrolase, has been widely used as a marker to study the involvement of peripheral nerve fibers in many diseases.</p><p><strong>Aim and objectives: </strong>To evaluate the change in cutaneous nerve fiber staining and distribution from pre-treatment and post completion of multidrug therapy through the expression of PGP9.5 and to assess PGP9.5 as a marker of treatment response.</p><p><strong>Materials and methods: </strong>In this prospective single-center observational study, skin biopsy was taken in patients with leprosy, having areas of nerve function impairment (NFI), based on findings of nerve conduction studies (NCSs), but not having lesions or impaired tactile or thermal impairment clinically. The thin nerve fiber density in the clinically normal skin in areas supplied by nerve showing changes of sensory neuropathy was evaluated to study the density of the fibers. A second biopsy was taken at the end of treatment from a site near the previous site to assess the changes in intra-epidermal nerve fiber staining and distribution.</p><p><strong>Results: </strong>Thirty-three patients were recruited in the present study (24 males and 9 females). Pre-treatment, 27 patients had abnormal NCSs, while six patients did not have any evidence of neuropathy on NCSs. Staining for nerve fibers using PGP9.5; in the epidermis was positive in five patients pre-treatment and 11 patients post treatment (<i>P</i> = 0.181). Staining in the dermis revealed positivity in 14 pre-treatment, which increased to 18 post treatment (<i>P</i> = 0.342). Adnexae showed positivity in five patients pre-treatment and increased to 17 post treatment (<i>P</i> = 0.005).</p><p><strong>Conclusion: </strong>A reduced PGP9.5 staining in the epidermal, dermal, and adnexal regions was seen in leprosy patients, which improved post treatment. Thus, PGP9.5 may serve as a marker of NFI and treatment response.</p>","PeriodicalId":13335,"journal":{"name":"Indian Dermatology Online Journal","volume":"15 4","pages":"599-604"},"PeriodicalIF":1.9,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11265736/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinico-Epidemiologic Profile and Response to Levocetirizine in Chronic Spontaneous Urticaria: A Retrospective Cohort Study from a Tertiary Care Center in North India.","authors":"Raihan Ashraf, Anuradha Bishnoi, Hitaishi Mehta, Davinder Parsad, Muthu Sendhil Kumaran","doi":"10.4103/idoj.idoj_703_23","DOIUrl":"https://doi.org/10.4103/idoj.idoj_703_23","url":null,"abstract":"<p><strong>Background: </strong>Comprehensive long-term follow-up data regarding chronic spontaneous urticaria (CSU) among general populations, especially from the Indian subcontinent is scanty.</p><p><strong>Aim and objectives: </strong>The aim of the study were to analyze the clinico-epidemiological profile, comorbidities of CSU patients, and factors affecting patient response to various doses of levocetirizine.</p><p><strong>Materials and methods: </strong>In this retrospective cohort study, complete history regarding demographic profile, clinical examination, investigations, treatment given, and follow-up details of all CSU patients attending urticaria clinic between 2010 and 2019 were analyzed. These were considered variables to determine the factors playing a role in response to various doses of levocetirizine.</p><p><strong>Results: </strong>Totally, 1104 files of CSU were analyzed. The male-to-female ratio was 1:1.5 with a mean age of 33.03 ± 14.33 years. Thyroid dysfunction and atopy were seen in 142 (12.8%) and 184 (16.7%) patients, respectively. Vitamin D deficiency and high serum immunoglobulin E (IgE) levels were seen in 461 (41.7%) and 340 (30.7%) patients, respectively. Immunosuppressives were required at some point in 196 (17.7%) patients. Patients with higher levels of serum IgE and D-dimer (<i>P</i> < 0.05) were found to require frequent updosing of levocetirizine, while age, sex, duration of illness, presence of angioedema, co-morbidities, identifiable precipitating factors, presence of diurnal variation, family history, and vitamin D deficiency were found to not have an effect on levocetirizine dosing.</p><p><strong>Conclusion: </strong>Ours is a large single-center study exemplifying the biomarkers including baseline serum IgE and D-dimer levels, which could identify a CSU patient who could warrant a higher dose of antihistamine/antihistamine refractory urticaria.</p>","PeriodicalId":13335,"journal":{"name":"Indian Dermatology Online Journal","volume":"15 4","pages":"630-633"},"PeriodicalIF":1.9,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11265761/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Selumetinib-A Comprehensive Review of the New FDA-Approved Drug for Neurofibromatosis.","authors":"Surajit Gorai, Gyanesh Rathore, Kinnor Das","doi":"10.4103/idoj.idoj_569_23","DOIUrl":"https://doi.org/10.4103/idoj.idoj_569_23","url":null,"abstract":"","PeriodicalId":13335,"journal":{"name":"Indian Dermatology Online Journal","volume":"15 4","pages":"701-705"},"PeriodicalIF":1.9,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11265740/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Human Seminal Plasma Allergy Diagnosed by Prick Test Using Seminal Plasma.","authors":"Koki Soda, Risa Ikutama, Toshio Hasegawa","doi":"10.4103/idoj.idoj_415_23","DOIUrl":"https://doi.org/10.4103/idoj.idoj_415_23","url":null,"abstract":"","PeriodicalId":13335,"journal":{"name":"Indian Dermatology Online Journal","volume":"15 4","pages":"643-645"},"PeriodicalIF":1.9,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11265744/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141763976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Painful Swelling in a Case of Neurofibromatosis 1: An Intriguing Entity.","authors":"Shraddha P Kote, Bhagyashree B Supekar, Jayesh I Mukhi","doi":"10.4103/idoj.idoj_145_23","DOIUrl":"https://doi.org/10.4103/idoj.idoj_145_23","url":null,"abstract":"","PeriodicalId":13335,"journal":{"name":"Indian Dermatology Online Journal","volume":"15 4","pages":"646-648"},"PeriodicalIF":1.9,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11265767/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Topical Tofacitinib for the Treatment of Alopecia Areata.","authors":"Siddhi B Chikhalkar, Swati Prasanna, Tejas Vishwanath","doi":"10.4103/idoj.idoj_535_23","DOIUrl":"https://doi.org/10.4103/idoj.idoj_535_23","url":null,"abstract":"<p><strong>Background: </strong>Alopecia areata (AA) is an autoimmune disease of the hair follicles. Although some cases resolve spontaneously, many patients require some form of treatment, including corticosteroids and vitamin D analogues, among others. Cytokine signaling in autoimmune disorders and their inhibition have been the prime objective in therapeutic research over the past few years. Janus kinase inhibitors such as tofacitinib have shown efficacy in the treatment of AA. The present study aimed to evaluate the efficacy of a novel formulation of topical tofacitinib compared to vehicle in patients with AA.</p><p><strong>Materials and methods: </strong>A prospective, non-blinded, intrasubject vehicle-controlled study was conducted in patients with AA for a total duration of 6 months. A 2% tofacitinib citrate ointment was compounded in the pharmacy. Tofacitinib tablets (5 mg) were crushed and mixed in white soft paraffin to produce 2% ointment. A thin layer of this ointment was applied to the treatment patch, while the control patches received the application of the vehicle twice daily. Both patches in each patient were evaluated for percentage change in severity of alopecia tool [SALT] score after 24 weeks as the primary outcome. This was graded as excellent response (>50% improvement), intermediate response (25-50%), mild response (5-25%), and no response (<5% improvement). Trichoscopy and hair pull test were evaluated as secondary outcomes.</p><p><strong>Results: </strong>The present study included 30 patients with AA having a median age of 27 years. Among 30 patients, 40% achieved excellent response (>50% change in the SALT score) over six months of treatment. The mean SALT score was significantly reduced from baseline to six months of treatment (mean [95% CI]: 4.3 [1.9-6.3]; <i>P</i> = 0.001). The control patch had substantially higher positive results in the final hair pull test, indicating disease activity (Treatment: 10% vs. Control: 86.7%, <i>P</i> < 0.001). Compared to the control patch, the prevalence of upright hair (10.0% vs. 80.0%) and terminal hair (3.3% vs. 70.0%) were significantly higher in the treatment patch (<i>P</i> < 0.001). No serious adverse effects were reported during the study duration.</p><p><strong>Limitations: </strong>Sample size was small and the followup was not long enough to study the full effects of tofacitinib, as well as maintenance of remission or relapse after discontinuation.</p><p><strong>Conclusion: </strong>Topical tofacitinib proved to be an efficacious and well-tolerated treatment modality for AA with no adverse effects reported during this study.</p>","PeriodicalId":13335,"journal":{"name":"Indian Dermatology Online Journal","volume":"15 4","pages":"624-629"},"PeriodicalIF":1.9,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11265738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipoid Proteinosis: A Rare Case Report and Review of Literature.","authors":"Damini Verma, Vibhu Mendiratta, Vidya Yadav, Anjali Birla, Amol Srivastava","doi":"10.4103/idoj.idoj_710_23","DOIUrl":"10.4103/idoj.idoj_710_23","url":null,"abstract":"","PeriodicalId":13335,"journal":{"name":"Indian Dermatology Online Journal","volume":"15 5","pages":"866-869"},"PeriodicalIF":1.9,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444465/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Levothyroxine-Induced Systemic Lupus Erythematosus in a Patient with Hypothyroidism: A Rare Case Report.","authors":"Angoori G Rao, M Naresh, Praveen Kumar, Anmisha Bandaru","doi":"10.4103/idoj.idoj_663_23","DOIUrl":"10.4103/idoj.idoj_663_23","url":null,"abstract":"","PeriodicalId":13335,"journal":{"name":"Indian Dermatology Online Journal","volume":"15 5","pages":"879-881"},"PeriodicalIF":1.9,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444427/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rectosigmoid Adenocarcinoma Presenting as an Umbilical Nodule: A Rare Presentation.","authors":"Preema Sinha, Akansha Tripathi, Manoj G Madakshira, Abhishek Mahato, Sampoorna R Chaudhary","doi":"10.4103/idoj.idoj_460_23","DOIUrl":"https://doi.org/10.4103/idoj.idoj_460_23","url":null,"abstract":"","PeriodicalId":13335,"journal":{"name":"Indian Dermatology Online Journal","volume":"15 4","pages":"655-656"},"PeriodicalIF":1.9,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11265745/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of the Clinical Efficacy of Rituximab Infusion and Dexamethasone-Cyclophosphamide Pulse Therapy and Their Effect on Serum Th1, Th2, and Th17 Cytokines in Pemphigus Vulgaris-A Prospective, Nonrandomized, Comparative Pilot Study.","authors":"Sujay Khandpur, Preeti Sharma, Vinod K Sharma, Dayasagar Das, Alpana Sharma, Neetu Bhari, Vishnubhatla Sreenivas","doi":"10.4103/idoj.idoj_558_23","DOIUrl":"10.4103/idoj.idoj_558_23","url":null,"abstract":"<p><strong>Background: </strong>Rituximab infusion and dexamethasone-cyclophosphamide pulse (DCP) are the two most popular regimens used in pemphigus vulgaris (PV) in India.</p><p><strong>Objective: </strong>The present study compared the clinical efficacy of rituximab and DCP in Indian PV patients and their effects on serum Th1,2, and 17 cytokine levels.</p><p><strong>Materials and methods: </strong>A total of 37 patients received DCP (Group A, <i>n</i> = 22) or rituximab (Group B, rheumatoid arthritis protocol (<i>n</i> = 15)) as per patients' preference. They were monitored for clinical response, adverse events (AEs), changes in serum anti-desmoglein-1,3 antibody titers and Th1,2 and 17 cytokine levels at baseline and weeks 20 and 52.</p><p><strong>Results: </strong>The proportion of patients attaining disease control, remission, and relapse in groups A and B were 82% and 93%; 73% and 93%; and 27% and 50%, respectively, after a median duration of 2 months each for disease control; 4 and 4.5 months for remission; and 5 and 7 months for relapse post remission. The musculoskeletal AEs were the highest in the two groups. Significant and comparable decreases in anti-dsg1 and 3 titers from baseline to weeks 20 and 52 were observed in both groups. Th1 and Th17 cytokine levels decreased, while Th2 cytokines increased post-treatment in both groups. However, no correlation was found between change in body surface area of involvement by PV and anti-dsg titers and cytokine levels before and after therapy in both groups.</p><p><strong>Conclusion: </strong>Comparable clinical efficacy between DCP and rituximab was observed.</p>","PeriodicalId":13335,"journal":{"name":"Indian Dermatology Online Journal","volume":"15 3","pages":"464-472"},"PeriodicalIF":1.7,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11152478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141283607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}